DPP4 and type 2 diabetes mellitus: This study aimed to provide real‐world evidence on the comparative cardiovascular safety of low‐affinity cardiac mitoKATP channel sulfonylureas and DPP‐4 inhibitors, as well as high‐affinity sulfonylureas versus DPP‐4 inhibitors, in a nationwide population of patients with type 2 diabetes.